Chromadex Corp
NASDAQ:CDXC
Chromadex Corp
NASDAQ:CDXC
Price:
3.4 USD
Market Closed
Updated:
Apr 25, 2024
Chromadex Corp
Operating Income
Last
Value
3-Years CAGR
5-Years CAGR
|
Chromadex Corp
Operating Income Peer Comparison
Comparables:
TMO
DHR
WST
A
IQV
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Chromadex Corp
NASDAQ:CDXC
|
Operating Income
-$5.6m
|
CAGR 3-Years
34%
|
CAGR 5-Years
30%
|
CAGR 10-Years
-3%
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Operating Income
$7.3B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
14%
|
CAGR 10-Years
15%
|
|
|
Danaher Corp
NYSE:DHR
|
Operating Income
$5.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
12%
|
CAGR 10-Years
5%
|
|
|
West Pharmaceutical Services Inc
NYSE:WST
|
Operating Income
$705.1m
|
CAGR 3-Years
19%
|
CAGR 5-Years
23%
|
CAGR 10-Years
16%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Operating Income
$1.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
6%
|
CAGR 10-Years
16%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Operating Income
$2.1B
|
CAGR 3-Years
38%
|
CAGR 5-Years
21%
|
CAGR 10-Years
16%
|
See Also
What is Chromadex Corp's Operating Income?
Operating Income
-5.6m
USD
-5.6m
USD
Based on the financial report for Dec 31, 2023, Chromadex Corp's Operating Income amounts to -5.6m USD.
What is Chromadex Corp's Operating Income growth rate?
Operating Income CAGR 10Y
-3%
-3%
Over the last year, the Operating Income growth was 70%. The average annual Operating Income growth rates for Chromadex Corp have been 34% over the past three years , 30% over the past five years , and -3% over the past ten years .
You don't have any saved screeners yet
